The Breakthrough in Cholesterol Management: Enlicitide's Promising Results

A groundbreaking clinical trial has revealed that enlicitide, an investigational oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor developed by Merck, dramatically lowers low-density lipoprotein cholesterol (LDL-C, often called "bad" cholesterol) by up to 60% in high-risk patients. This phase 3 study, known as CORALreef Lipids, marks a potential game-changer for cardiovascular disease (CVD) prevention, offering a convenient pill alternative to injectable therapies. Published in the New England Journal of Medicine in February 2026, the trial's findings highlight enlicitide's efficacy in adults with atherosclerotic cardiovascular disease (ASCVD) or at high risk, many of whom struggle to reach LDL-C targets despite statins.

Cardiovascular disease remains the leading cause of death in the United States, claiming nearly 482,000 lives in 2023 alone, with high cholesterol as a key modifiable risk factor affecting tens of millions of Americans. Approximately 37 million U.S. adults have total cholesterol above 200 mg/dL, and despite available treatments, fewer than half of high-risk patients achieve guideline-recommended LDL-C levels below 70 mg/dL or 55 mg/dL. Enlicitide addresses this gap by mimicking the potent LDL-lowering effects of injectable PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent) in an easy-to-take daily tablet.

Understanding LDL Cholesterol and PCSK9's Role

LDL cholesterol is a waxy substance essential for cell building but dangerous in excess, as it builds up in artery walls, forming plaques that narrow blood flow and raise risks of heart attacks and strokes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a liver protein that regulates LDL receptor (LDLR) levels on liver cells. PCSK9 binds to LDLR, marking it for degradation, reducing the liver's ability to clear LDL from the blood.

Statins, the first-line therapy, lower LDL-C by 20-50% by inhibiting cholesterol synthesis and upregulating LDLR. However, some patients experience statin intolerance or insufficient response. Injectable PCSK9 monoclonal antibodies block PCSK9 extracellularly, boosting LDLR recycling and slashing LDL-C by 50-70%, but self-injection every two weeks, high costs (though reduced), and access barriers limit use to about 1-2% of eligible patients.

Enlicitide, a synthetic macrocyclic peptide, innovates by orally binding PCSK9 with high affinity, preventing LDLR interaction without antibodies' complexity. Discovered through Merck's peptide platform, it leverages cell-permeating enhancers for gut absorption, achieving systemic PCSK9 inhibition comparable to injectables.

Inside the CORALreef Lipids Phase 3 Trial

The CORALreef Lipids trial (NCT06008756) was a multinational, double-blind, randomized, placebo-controlled study enrolling 2,909 adults (mean age 63, 39% women) from 2023-2025 across 59 sites in 17 countries, including U.S. centers. Participants had established ASCVD with LDL-C ≥55 mg/dL or high risk (e.g., diabetes, hypertension) with LDL-C ≥70 mg/dL, on stable statins ± ezetimibe. Randomized 2:1 to enlicitide 20 mg daily or placebo for 52 weeks, baseline LDL-C averaged 96 mg/dL.

Primary endpoint: percent change in LDL-C at week 24. Secondary: LDL-C at week 52, non-HDL-C, apolipoprotein B (apoB), lipoprotein(a) [Lp(a)] at week 24. Nearly all continued background therapy, reflecting real-world use. Led by investigators like Ann Marie Navar, M.D., Ph.D., from UT Southwestern Medical Center, the trial emphasized diverse high-risk populations.

Key Findings: 60% LDL Reduction and Beyond

At 24 weeks, enlicitide slashed LDL-C by 57.1% (95% CI -61.8 to -52.5) versus +3.0% placebo (between-group difference -55.8%; P<0.001). Sustained at 52 weeks: -47.6% versus placebo. Two-thirds achieved ≥50% reduction and targets <70 mg/dL; 40% reached <55 mg/dL. Secondary lipids improved markedly: non-HDL-C -53.4%, apoB -50.3%, Lp(a) -28.2% (all P<0.001), signaling comprehensive atherogenic risk reduction.

A companion HeFH trial (CORALreef HeFH) in 303 patients showed -58.2% LDL-C reduction at 24 weeks, confirming efficacy in genetic hypercholesterolemia. Post-hoc analyses reinforced robustness across subgroups, including statin-intolerant patients.

Safety and Long-Term Tolerability

Enlicitide's safety mirrored placebo: adverse events 64% vs. 65%, serious AEs 10% vs. 12%, discontinuations due to AEs 3.1% vs. 4.1%. No deaths linked to treatment; common AEs (headache, nasopharyngitis) were mild. Liver enzymes, CK, neurocognitive events unchanged. Long-term 52-week data showed consistent profile, no new signals.

This tolerability supports daily use, contrasting injectables' injection-site reactions (5-10%). Merck's macrocyclic design minimizes off-target effects.

Enlicitide vs. Statins and Injectables: A New Standard?

Statins reduce LDL 20-55%; high-intensity like atorvastatin 40 mg ~50%. PCSK9 injectables add 50-70% further drop but biweekly dosing limits adherence (50-60%). Enlicitide's oral convenience could boost persistence, matching injectable efficacy (55-60%) without needles. Cost may drop post-patent; generics unlikely soon.

Ongoing CORALreef Outcomes evaluates CV events, pivotal for label expansion.

Patient Impact: Closing the LDL Treatment Gap

~18 million Americans have ASCVD; 93 million 10-year risk ≥7.5%, yet statin use ~50%, goal attainment <30% high-risk. Oral enlicitide simplifies intensification, aiding intolerance (10-15%) or non-responders. HeFH patients (1:250) benefit hugely, often needing apheresis.

Real-world: high adherence projected >80% vs. 60% injectables. Equity gains for underserved via primary care.

Academic Roots: UT Southwestern's Legacy

UT Southwestern pioneered PCSK9: Michael Brown/Joseph Goldstein (1985 Nobel LDLR), Helen Hobbs/Jonathan Cohen (2003 PCSK9 gene). Dallas Heart Study identified loss-of-function variants halving CHD risk, inspiring inhibitors. Navar, leveraging this, led CORALreef Lipids, advancing translation from bench to bedside.

UTSW ranks #2 globally endocrinology, fostering trials like this via McDermott Center.

Regulatory Path and Future Outlook

Merck plans FDA NDA Q2 2026, priority review voucher granted Dec 2025. If approved, first oral PCSK9 inhibitor. Pediatric HeFH, combo trials ongoing. Market: $2-3B peak, challenging $1B injectables via convenience.

Learn more at the CORALreef Lipids trial page.

Photo by Melany @ tuinfosalud.com on Unsplash

Transforming CVD Prevention Nationwide

With 48.9 million U.S. adults high total cholesterol, enlicitide could avert thousands MI/strokes yearly. Integrates guidelines: ACC 2026 emphasizes early aggressive lowering. Academic trials validate, paving population impact.

Read the full NEJM publication and JAMA HeFH results.